Eli Lilly and Company (NYSE: LLY) presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD). The data were shared at the 2023 Alzheimer's Association International Conference .
Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer s disease patients, lowering their risk of.
Lilly (LLY) Announces Results from Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.